Harms AEs of any grade were comparable between the two arms (79% and 88% in the nivolumab- and everolimus-treated patients, respectively); while the rate of grade 3 or 4 AEs was lower in the nivolumab group when compared to that of the everolimus group (19% vs. [...] Unlike the CheckMate025 phase III trial which aimed to evaluate the performance of nivolumab in comparison to a viable second-line standard treatment (everolimus) for RCC, the above-mentioned studies aimed at evaluating the activity and toxicity of nivolumab in a single cohort of eligible patients receiving nivolumab monotherapy,12 or comparing the efficacy and safety of three dose levels of nivol [...] In the nivolumab group 227 of the 410 patients (55%) and 260 of the 411 patients (63%) in the everolimus group received subsequent systemic therapy. [...] More recently the Heng criteria which better reflects treatment with targeted agents has come into regular use and for the purposes of clinical trials.24-26 Advances in our understanding of RCC biology and the development of new therapeutic agents (targeted therapies / antiangiogenic agents), in particular for the clear-cell subtype of RCC, have resulted in the availability of a number of new trea [...] The incidence of dose delays was 51% in the nivolumab group (207 of the 406 treated patients) and 66% in the everolimus group (262 of the 397 treated patients).
- Pages
- 58
- Published in
- Ottawa, ON, CA
